We collectively continue to misunderstand mAbs.
Post# of 153832
(Total Views: 969)
Posted On: 11/15/2020 10:09:29 PM
We collectively continue to misunderstand mAbs.
Monoclonal antibodies are just single antibodies that have been cloned, expanding their numbers by many orders of magnitude.
The target of the antibody is key to its functions, as well as whether it is an agonist, antagonist, or agglutinating antibody.
Eli Lilly and Regeron target the virus and are likely the mAbs to which Dr. Fauci was referring, as evolution of the viral spike may render these useless.
Leronlimab just blocks the binding site of the CCR5 receptor, antagonizing its function. It does not make a difference whether this is done to mitigate immune dysfunction in Covid, stop HIV viral entry, or block Tregs to reduce cancer metastasis.
We in large part react as though Dr. Fauci is addressing mAbs such as leronlimab or lenzilumab, when it appears he has ignore these throughout the pandemic.
I'm not expecting any immediate change in his focus. Perhaps after EUA or approval from FDA he'll recognize the other uses for mAbs.
Monoclonal antibodies are just single antibodies that have been cloned, expanding their numbers by many orders of magnitude.
The target of the antibody is key to its functions, as well as whether it is an agonist, antagonist, or agglutinating antibody.
Eli Lilly and Regeron target the virus and are likely the mAbs to which Dr. Fauci was referring, as evolution of the viral spike may render these useless.
Leronlimab just blocks the binding site of the CCR5 receptor, antagonizing its function. It does not make a difference whether this is done to mitigate immune dysfunction in Covid, stop HIV viral entry, or block Tregs to reduce cancer metastasis.
We in large part react as though Dr. Fauci is addressing mAbs such as leronlimab or lenzilumab, when it appears he has ignore these throughout the pandemic.
I'm not expecting any immediate change in his focus. Perhaps after EUA or approval from FDA he'll recognize the other uses for mAbs.
(9)
(0)